I've just sat through today's video presentation, again. Can't...

I've just sat through today's video presentation, again. Can't help but feel that I've done my dough here so probably will stay away from the capital rise. The strategy here is a bit puzzling. The only reason that I can think of for a company to deprioritise its core technology in order to become an intermediary between eastern biotechs, western government agencies and financiers is that they have lost faith in their own technology and the ability to do a deal for AD-214. While the company may have some useful competencies as an intermediary there is no genuine competitive advantage that would likely generate great value. The deprioritisation of AD-214 can only detract from getting a deal. How do you sell tech without R&D? Why would a prospective buyer of AD-214 see value where the company cannot? While Tim says that the cap raise is to get an East/West deal over the line, I hope that rather than waiting for the phone to ring he is pulling out all stops behind the scenes to get an AD-214 deal. Without it 1AD seems to be banking on having a minority interest in an East/West project to resuscitate the share price sufficiently in the short term for a sensible capital raise. What a mess.